No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VCNX Vaccinex
- 6.1300
- -0.3800-5.84%
Close Jun 18 16:00 ET
- 6.3600
- +0.2300+3.75%
Post 16:51 ET
9.71MMarket Cap-238P/E (TTM)
6.5300High6.0100Low16.14KVolume6.4000Open6.5100Pre Close100.29KTurnover2.64%Turnover RatioLossP/E (Static)1.58MShares83.558852wk High6.84P/B3.75MFloat Cap4.432052wk Low--Dividend TTM612.33KShs Float2568.3000Historical High--Div YieldTTM7.99%Amplitude4.4320Historical Low6.2130Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Vaccinex Completes Last Patient Visit In Randomized, SIGNAL-AD Phase 1b/2 Study Of Pepinemab Treatment For Alzheimer's Disease
Express News | Vaccinex Reports Completion of Last Patient Visit in Randomized, Signal-Ad Phase 1B/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex(VCNX.US) 10% Shareholder Buys US$9,210.05 in Common Stock
$Vaccinex(VCNX.US)$ 10% Shareholder FRIEDBERG ALBERT purchased 1,818 shares of common stock on May 29, 30, 2024 at an average price of $5.066 for a total value of $9,210.05. This transaction involves
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results.SentinelOne reported quarterly losses of 23 cents per share, which
12 Health Care Stocks Moving In Friday's Intraday Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) share
Vaccinex Shares Resume Trade
Vaccinex Shares Resume Trade
Comments
$Vaccinex(VCNX.US$
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints incl...
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints incl...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg